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MICAbstract We have described the conventional and microwave method for the synthesis of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-1H-imidazol-1-yl)(aryl)amides 3a–l. It
is observed that the solvent-free microwave thermolysis is a convenient, rapid, high-yielding, and
environmental friendly protocol for the synthesis of quinoline based imidazole derivatives when
compared with conventional reaction in a solution phase. Antimicrobial activity of the newly syn-
thesized compounds is screened in vitro on the following microbial cultures: Escherichia coli (MTCC
443), Pseudomonas aeruginosa (MTCC 1688), Staphylococcus aureus (MTCC 96), Streptococcus
pyogenes (MTCC 442), Candida albicans (MTCC 227), Aspergillus niger (MTCC 282), Aspergillus
clavatus (MTCC 1323). All the synthesized bio-active molecules are tested for their in vitro antimi-
crobial activity by bioassay namely serial broth dilution. Among these compounds 3c, 3d, 3f, 3h and
3j show signiﬁcant potency against different microbial strains. All the compounds have been char-
acterized by IR, 1H NMR, 13C NMR and mass spectral data. On the basis of statistical analysis, it is
observed that these compounds give signiﬁcant co-relation.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.
Open access under CC BY-NC-ND license.1. Introduction
Combat against bacterial infections has resulted in the devel-
opment of a wide variety of antibiotics. After years of misuse
and overuse of antibiotics, bacteria are becoming antibiotic
resistant, resulting in a potential global health crisis. Fre-
quently, it is recommended to use new antibacterial agents
with enhanced broad-spectrum potency. Therefore, recent
efforts have been directed towards exploring novel antibacte-
rial agents (Moustafa et al., 2004). Apart from this, during
the past 20 years an increase of invasive fungal infections has
964been observed, particularly in immunosuppressed patients,
which are now, cause of morbidity and mortality. Autopsy
data in fact indicate that more than half of the patients who
die with malignancies are infected with Candida spp. and
increasing number with other fungi. Since the discovery of
amphotericin B, a number of different classes of antifungal
agents have been discovered. However, there is still a critical
need for new antimicrobial agents to treat life threatening
invasive mycoses (Andriole, 1999). In order to overcome this
rapid development of drug resistance, new agents should pref-
erably consist of chemical characteristics that clearly differ
from those of existing agents. In drug developing programs,
an essential component of the search for new leads is the syn-
thesis of molecules, which are novel yet resemble known bio-
logically active molecules by virtue of the presence of critical
structural features. Certain small heterocyclic molecules act
as highly functionalized scaffolds and are known pharmaco-
phores of a number of biologically active and medicinally use-
ful molecules (Thompson and Ellman, 1996).
Nitrogen bridgehead-fused heterocycles containing an imid-
azole ring are common structural motifs in pharmacologically
important molecules, with activities spanning a diverse range
of targets. The pharmacological interest of the imidazole ring
has been established, nitroimidazoles being extensively used in
therapy against amoebic, trichomonal, giardial and anaerobic
infections or as hypoxic cell radiosensitizers (Nair and
Nagarajan, 1983). Metronidazole and substituted imidazoles
arewell-tolerated drugs that are potentially active against Leish-
mania, but their use in the treatment of cutaneous and visceral
leishmaniasis has produced conﬂicting results (Gangneux
et al., 1999). Clotrimazole is an antifungal medication com-
monly used in the treatment of fungal infections such as vaginal
yeast infections, oral thrush and ringworm. The imidazole moi-
ety which incorporates both p-excessive and p-deﬁcient charac-
teristics has proven to be amaster key in the range of drug target
families (Abdel-Meguid et al., 1994; Muller, 2003). Compounds
incorporating the imidazole scaffold are known as inhibitors of
p38 MAPK (Laufer et al., 2004), JNK (Lisnock et al., 2002), B-
Raf kinase (Takle et al., 2006), transforming growth factor b-1
(TGF-b1) type 1 receptor kinase (Laping et al., 2002) and
acyl-CoA: cholesterol O-acyl transferase (ACAT) (Riddell
et al., 1996). Imidazoles substituted with 2-arylamino function-
ality have been reported to have potent and selective agonist
activity at a2-adrenoceptors (Munk et al., 1997).
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Primaquine The quinoline ring system is an important structural unit in
naturally occurring quinoline alkaloids, therapeutics and syn-
thetic analogues with interesting biological activities. Some
derivatives containing quinoline ring system have been shown
to possess useful pharmacological activities, for example Dib-
ucaine hydrochloride is an anaesthetic, Primaquine is an anti-
malarial agent, Apomorphine is antiparkinsonian and
Oxamniquine is schistosomicidal. Quinoline derivatives have
been developed for the treatment of many diseases like malaria
(Lutz et al., 1946), HIV (Ahmed et al., 2010), tumour (Atwell
et al., 1989) and antibacterial infections (Munawar et al.,
2008). Recently, substituted quinolines have also been reported
to act as antagonists for endothelin (Cheng et al., 1996), 5HT3
(Anzini et al., 1995), NK-3 (Giardina et al., 1997) and leuko-
triene D4 receptor (Gauthier et al., 1990). They also function
as inhibitors of gastric (H+/K+)-ATPase (Ife et al., 1992),
dihydroorotate dehydrogenase (Chen et al., 1990) and 5-
lipoxygenase (Musser et al., 1987).
The exploitation of microwaves for assisting different
organic reactions has blossomed into an important tool in syn-
thetic organic chemistry. In the present programme our aim is
to develop an efﬁcient procedure for the synthesis of new hetero-
cyclic systems containing imidazole and quinoline derivatives.
Due to the timeless ease of workability and eco-friendliness,
microwaves provide alternative to environmentally unaccept-
able procedures. Microwave energy offers numerous beneﬁts
in performing synthesis including increased reaction rates, yield
enhancements and cleaner chemistries. Due to greater selectiv-
ity, rapid transfers of energy, signiﬁcant practical simplicity
and pure product, microwave assisted reactions have greater
advantage over conventionalmethods. Toxicity of conventional
methodpromptedus to explore other greenprocesses.Reactions
without using solvent usually with closed vessel in microwave
reaction system are currently popular among the synthetic
chemists to create eco-friendly atmosphere.
In continuation to this, it is our ongoing project to synthe-
size bio-active heterocyclic compounds (Desai et al., 2011b,
2011c, 2011d, 2014, 2011f). Due to this high level of impor-
tance and utility, an ever increasing amount of research has
been focused on the functionalization of imidazole and quino-
line moieties. We have synthesized a series of N-(4-((2-chloro-
quinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-1H-imi-
dazol-1-yl)(aryl)amides (3a–l) (Scheme 1) by conventional and
microwave methods. The conditions of conventional and
microwave methods are shown in Table 1. The structures of
synthesized compounds are assigned on the basis of IR, 1H
NMR, 13C NMR, and mass spectral data. These compounds
are evaluated for their antimicrobial screening on different
strains of bacteria and fungi.
2. Experimental part
2.1. Materials and physical measurements
Completion of reaction and purity of all compounds were
checked on aluminium coated TLC plates 60 F245 (E. Merck)
using n-hexane:ethyl acetate (7.5:2.5 V/V) as mobile phase and
visualizedunder ultraviolet (UV) light or iodine vapour.Melting
points were determined on an electro thermal melting point
apparatus and were reported uncorrected. Elemental analysis
(% C, H, N) was carried out by a Perkin-Elmer 2400 CHN ana-
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Scheme 1 Synthetic route for the preparation of title compounds (3a–l).
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kin-Elmer FT-IR spectrophotometer in KBr. 1H NMR and
13C NMR spectra were recorded on Bruker (400 MHz) spec-
trometer using DMSO-d6 as a solvent and TMS as an internal
standard. Chemical shifts were reported in parts per million
(ppm). Mass spectra were scanned on Shimadzu LCMS 2010
spectrometer. Anhydrous reactions were carried out in oven-
dried glassware in nitrogen atmosphere. Microwave assisted
reactions were carried out in Synthos-3000.
2.2. Preparation methods and physical data of synthesized
compounds (3a–l)
2.2.1. Procedure for the synthesis of 2-chloroquinoline-3-
carbaldehyde (1)
Compound 2-chloroquinoline-3-carbaldehyde (1) was pre-
pared according to the literature method (Meth-Cohn, 1993).
2.2.2. Procedure for the synthesis of 4-((2-chloroquinolin-3-
yl)methylene)-2-phenyloxazol-5(4H)-one (2)
2.2.2.1. Conventional method. A mixture of 2-chloroquinoline-
3-carbaldehyde (1) (47.75 g, 0.25 mol), hippuric acid (44.75 g,
0.25 mol), acetic anhydride (28.28 mL, 0.30 mol) and anhy-
drous sodium acetate (20.50 g, 0.25 mol) was taken in a
250 mL round bottom ﬂask and heated on an electric hot plate
with constant stirring. As soon as the mixture liqueﬁed com-
pletely, the ﬂask was transferred to a water bath and further
heated for 4 h, ethanol (100 mL) was added slowly to the ﬂask
and the mixture was allowed to stand overnight in refrigerator.
The crystalline product obtained was ﬁltered and washed with
ice-cold alcohol and then with boiling water, the crude product
was recrystallized from benzene.
2.2.2.2. Microwave method. A mixture of compound 2-chloro-
quinoline-3-carbaldehyde (1) (47.75 g, 0.25 mol), hippuric acid(44.75 g, 0.25 mol), acetic anhydride (28.28 mL, 0.30 mol) and
anhydrous sodium acetate (20.50 g, 0.25 mol) was taken in a
reaction vessel and mixed thoroughly. The mixture was irradi-
ated under microwave for 3 min at 300 W with constant shak-
ing and intermittent radiation of 30 s interval. Progress of the
reaction was monitored by TLC. Upon completion of reaction
the vessel was cooled, ethanol was added and the mixture was
kept overnight in the refrigerator. The crystalline product
obtained was ﬁltered and washed with ice cold alcohol and
then with boiling water, crude product was recrystallized from
benzene.
Yield – 68%; m.p. 232–234 C; IR (KBr, cm1): 3057, 3080
(C–H stretching, aromatic ring), 3011 (C–H stretching, –
CH‚C–), 1682 (C‚O stretching, imidazoline ring), 1609,
1570, 1527 (C‚N, C‚C, aromatic ring stretching), 1204
(C–O stretching), 961 (C–H bending, –CH‚C–), 743 (C–Cl
stretching); 1H NMR (400 MHz, DMSO-d6, d, ppm): 7.37–
8.30 (m, 10H, Qui-H, Ar-H), 7.61 (s, 1H, –C‚CH–); 13C
NMR (400 MHz, DMSO-d6, d, ppm): 114.7, 126.2, 126.4,
127.5, 127.6, 127.9, 128.1, 128.5, 128.8, 129.3, 131.3, 132.6,
136.1, 145.6, 152.4, 159.5, 166.3; LCMS (m/z): 334 (M+).
Anal. Calcd. for C19H11ClN2O2: C – 68.17%, H – 3.31%, N
– 8.37%; Found: C – 68.24%, H – 3.25%, N – 8.43%.2.2.3. General procedure of synthesis of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazol-1-yl)-(aryl)amides (3a–l)
2.2.3.1. Conventional method. 4-((2-Chloroquinolin-3-yl)meth-
ylene)-2-phenyloxazol-5(4H)-one (2) (3.34 g, 0.01 mol) was
heated with an equimolar quantity of N-aminoarylcarboxa-
mides (0.01 mol) in pyridine in an oil bath at 150–155 C for
6–8 h. Completion of reaction was monitored by TLC. Excess
of pyridine was distilled off. The mixture was poured into ice-
cold water and then required amount of conc. HCl was added
to neutralize the reaction mixture. The solid obtained was left
Table 1 Reaction conditions and physical parameters for compounds 3a–l.
Sr. No. –R Reaction time (h) for
conventional method
Yield (%) for
conventional method
Reaction time (min)
for microwave method
Yield (%) for
microwave method
M.P. (C)
3a –C6H5 8 71 4 77 203–205
3b C6H5–CH2- 7.5 68 4.5 74 233–235
3c –3-Cl–C6H4 7 70 3.5 75 193–195
3d –4-Cl–C6H4 9 72 5 74 270–272
3e –2,5-(Cl)2–C6H3 8 65 4.5 70 190–192
3f –4-F–C6H4 6.5 73 3 78 253–255
3g –3-NO2–C6H4 8 70 6 73 238–240
3h –4-NO2–C6H4 7.5 69 3.5 74 178–180
3i –2-OH–C6H4 8.5 63 4.5 69 189–191
3j –3-OH–C6H4 9 65 6 71 225–227
3k –2-OH-4-Cl–C6H3 7.5 72 4 76 240–242
3l –C5H4N 6 67 3 69 273–275
966 N.C. Desai et al.overnight, ﬁltered and washed with water. Product was dried
and recrystallized from ethanol (99%).
2.2.3.2. Microwave method. A mixture of 4-((2-chloroquinolin-
3-yl)methylene)-2-phenyloxazol-5(4H)-one (2) (3.34 g,
0.01 mol), N-aminoarylcarboxamides (0.01 mol), pyridine 2–3
drops in 10 mL of DMF was taken in a reaction vessel. The
reaction mixture was thoroughly mixed and irradiated in
microwave oven at 400 W intermittently at 30 s intervals for
a speciﬁed time Table 1. Completion of reaction was moni-
tored by TLC. The mixture was poured into ice-cold water
and then required amount of conc. HCl was added to neutral-
ize the reaction mixture. The solid obtained was left overnight,
ﬁltered and washed with water. Product was dried and recrys-
tallized from ethanol (99%).
2.2.3.3. Physical constants and characterization of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazol-1-yl)benzamide (3a). IR (KBr, cm1): 3341 (–NH
stretching, secondary amine), 3052, 3074 (C–H stretching, aro-
matic ring), 3011 (C–H stretching, –CH‚C–), 1711 (C‚O
stretching, amide), 1682 (C‚O stretching, imidazoline ring),
1611, 1581, 1535 (C‚N, C‚C, aromatic ring stretching),
940 (C–H bending, –CH‚C–), 748 (C–Cl stretching); 1H
NMR (400 MHz, DMSO-d6, d, ppm): 7.37–8.22 (m, 15H,
Qui-H, Ar-H), 7.52 (s, 1H, –CH‚C–), 8.58 (s, 1H, –NHCO–
linkage); 13C NMR (400 MHz, DMSO-d6, d, ppm): 111.2,
126.2, 127.4, 127.5, 127.7, 127.8, 128.2, 128.3, 128.5, 128.7,
129.2, 132.3, 132.6, 133.01, 133.5, 136.6, 137.2, 144.7, 145.5,
152.6, 168.3, 172.1; LCMS (m/z): 452 (M+). Anal. Calcd. for
C26H17ClN4O2: C – 68.95%, H – 3.78%, N – 12.37%; Found:
C – 68.89%, H – 3.83%, N –12.43%.
2.2.3.4. Physical constants and characterization of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazol-1-yl)-2-phenylacetamide (3b). IR (KBr, cm1):
3346 (–NH stretching, secondary amine), 3053, 3078 (C–H
stretching, aromatic ring), 3014 (C–H stretching, –CH‚C–),
2869 (C–H stretching, –CH2–), 1706 (C‚O stretching, amide),
1687 (C‚O stretching, imidazoline ring), 1608, 1579, 1520
(C‚N, C‚C, aromatic ring stretching), 1451, 963 (C–H bend-
ing, –CH2–, –CH‚C–), 752 (C–Cl stretching);
1H NMR
(400 MHz, DMSO-d6, d, ppm): 4.02 (s, 2H, –CH2–), 7.32–
8.19 (m, 15H, Qui-H, Ar-H), 7.50 (s, 1H, –CH‚C–), 8.56 (s,
1H, –NHCO– linkage); 13C NMR (400 MHz, DMSO-d6, d,ppm): 39.6, 111.1, 126.4, 126.7, 127.2, 127.4, 127.6, 127.9,
128.4, 128.2, 128.5, 128.8, 129.5, 132.6, 133.4, 134.7, 136.5,
137.3, 144.6, 145.4, 152.3, 168.4, 172.1; LCMS (m/z): 466
(M+). Anal. Calcd. for C27H19ClN4O2: C – 69.45%, H –
4.10%, N – 12.00%; Found: C – 69.39%, H – 4.17%, N –
12.06%.
2.2.3.5. Physical constants and characterization of 3-chloro-N-
(4-((2-chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-
dihydro-1H-imidazol-1-yl)benzamide (3c). IR (KBr, cm1):
3351 (–NH stretching, secondary amine), 3061, 3087 (C–H
stretching, aromatic ring), 3021 (C–H stretching, –CH‚C–),
1718 (C‚O stretching, amide), 1683 (C‚O stretching, imidaz-
oline ring), 1613, 1592, 1524 (C‚N, C‚C, aromatic ring
stretching), 989 (C–H bending, –CH‚C–), 752, 763 (C–Cl
stretching); 1H NMR (400 MHz, DMSO-d6, d, ppm): 7.42–
8.22 (m, 14H, Qui-H, Ar-H), 7.54 (s, 1H, –CH‚C–), 8.60 (s,
1H, –NHCO– linkage); 13C NMR (400 MHz, DMSO-d6, d,
ppm): 111.2, 126.7, 125.8, 127.4, 127.5, 127.6, 127.7, 128.4,
128.5, 128.7, 129.5, 129.7, 132.5, 132.8, 133.2, 134.2, 135.1,
136.3, 137.6, 144.7, 145.4, 152.4, 168.5, 172.2; LCMS (m/z):
486 (M+). Anal. Calcd. for C26H16Cl2N4O2: C – 64.08%, H
– 3.31%, N – 11.50%; Found: C – 64.14%, H – 3.25%, N –
11.43%.
2.2.3.6. Physical constants and characterization of 4-chloro-N-
(4-((2-chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-
dihydro-1H-imidazol-1-yl)benzamide (3d). IR (KBr, cm1):
3348 (–NH stretching, secondary amine), 3045, 3081 (C–H
stretching, aromatic ring), 3025 (C–H stretching, –CH‚C–),
1715 (C‚O stretching, amide), 1684 (C‚O stretching, imidaz-
oline ring), 1605, 1588, 1520 (C‚N, C‚C, aromatic ring
stretching), 980 (C–H bending, –CH‚C–), 748, 768 (C–Cl
stretching); 1H NMR (400 MHz, DMSO-d6, d, ppm): 7.40–
8.24 (m, 14H, Qui-H, Ar-H), 7.53 (s, 1H, –CH‚C–), 8.62 (s,
1H, –NHCO– linkage); 13C NMR (400 MHz, DMSO-d6, d,
ppm): 111.3, 126.7, 127.5, 127.6, 127.8, 128.1, 128.5, 128.6,
128.7, 129.3, 130.6, 131.1, 132.6, 133.4, 136.1, 137.3, 138.2,
144.8, 145.6, 152.4, 168.5, 172.1; LCMS (m/z): 486 (M+).
Anal. Calcd. for C26H16Cl2N4O2: C – 64.08%, H – 3.31%,
N – 11.50%; Found: C – 64.14%, H – 3.37%, N – 11.58%.
2.2.3.7. Physical constants and characterization of 2,5-dichloro-
N-(4-((2-chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-
dihydro-1H-imidazol-1-yl)benzamide (3e). IR (KBr, cm1):
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stretching, aromatic ring), 3017 (C–H stretching, –CH‚C–),
1721 (C‚O stretching, amide), 1692 (C‚O stretching, imidaz-
oline ring), 1617, 1591, 1511 (C‚N, C‚C, aromatic ring
stretching), 978 (C–H bending, –CH‚C–), 758, 773 (C–Cl
stretching); 1H NMR (400 MHz, DMSO-d6, d, ppm): 7.43–
8.26 (m, 13H, Qui-H, Ar-H), 7.55 (s, 1H, –CH‚C–), 8.67 (s,
1H, –NHCO– linkage); 13C NMR (400 MHz, DMSO-d6, d,
ppm): 111.2, 126.2, 127.4, 127.7, 127.8, 128.4, 128.5, 128.7,
128.8, 129.1, 129.4, 132.2, 132.5, 132.6, 132.8, 133.2, 134.7,
136.6, 137.6, 144.5, 145.3, 152.2, 168.3, 172.2; LCMS (m/z):
520 (M+). Anal. Calcd. for C26H15Cl3N4O2: C – 59.85%, H
– 2.90%, N – 10.74%; Found: C – 59.79%, H – 2.97%, N –
10.69%.
2.2.3.8. Physical constants and characterization of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazol-1-yl)-4-ﬂuorobenzamide (3f). IR (KBr, cm1):
3364 (–NH stretching, secondary amine), 3054, 3090 (C–H
stretching, aromatic ring), 3021 (C–H stretching, –CH‚C–),
1726 (C‚O stretching, amide), 1695 (C‚O stretching, imidaz-
oline ring), 1621, 1582, 1535 (C‚N, C‚C, aromatic ring
stretching), 1152 (C–F stretching) 950 (C–H bending, –
CH‚C–), 762 (C–Cl stretching); 1H NMR (400 MHz,
DMSO-d6, d, ppm): 7.47–8.30 (m, 14H, Qui-H, Ar-H), 7.58
(s, 1H, –CH‚C–), 8.71 (s, 1H, –NHCO– linkage); 13C
NMR (400 MHz, DMSO-d6, d, ppm): 111.4, 115.4, 126.5,
127.6, 127.8, 127.9, 128.1, 128.4, 128.6, 128.7, 129.2, 129.3,
132.1, 133.3, 136.6, 137.2, 144.7, 145.8, 152.6, 166.8, 168.4,
172.4; LCMS (m/z): 470 (M+). Anal. Calcd. for C26H16ClFN4-
O2: C – 66.32%, H – 3.42%, N – 11.90%; Found: C – 66.37%,
H – 3.39%, N – 11.94%.
2.2.3.9. Physical constants and characterization of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazol-1-yl)-3-nitrobenzamide (3g). IR (KBr, cm1):
3351 (–NH stretching, secondary amine), 3059, 3083 (C–H
stretching, aromatic ring), 3019 (C–H stretching, –CH‚C–),
1720 (C‚O stretching, amide), 1681 (C‚O stretching, imidaz-
oline ring), 1617, 1592, 1531 (C‚N, C‚C, aromatic ring
stretching), 1462 (NO2 group, asymmetric stretching), 1351
(NO2 group, symmetric stretching), 963 (C–H bending, –
CH‚C–), 762 (C–Cl stretching); 1H NMR (400 MHz,
DMSO-d6, d, ppm): 7.45–8.28 (m, 14H, Qui-H, Ar-H), 7.57
(s, 1H, –CH‚C–), 8.69 (s, 1H, –NHCO– linkage); 13C
NMR (400 MHz, DMSO-d6, d, ppm): 111.5, 123.1, 126.4,
127.3, 127.6, 127.7, 127.9, 128.3, 128.6, 128.8, 129.1, 129.2,
132.5, 133.4, 134.1, 134.7, 136.3, 137.5, 144.7, 145.6, 147.9,
152.5, 168.7, 172.3; LCMS (m/z): 497 (M+). Anal. Calcd. for
C26H16ClN5O4: C – 62.72%, H – 3.24%, N – 14.07%; Found:
C – 62.67%, H – 3.17%, N – 14.12%.
2.2.3.10. Physical constants and characterization of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazol-1-yl)-4-nitrobenzamide (3h). IR (KBr, cm1):
3360 (–NH stretching, secondary amine), 3048, 3075 (C–H
stretching, aromatic ring), 3027 (C–H stretching, –CH‚C–),
1718 (C‚O stretching, amide), 1679 (C‚O stretching, imidaz-
oline ring), 1611, 1582, 1520 (C‚N, C‚C, aromatic ring
stretching), 1457 (NO2 group, asymmetric stretching), 1343
(NO2 group, symmetric stretching), 982 (C–H bending, –
CH‚C–), 772 (C–Cl stretching); 1H NMR (400 MHz,DMSO-d6, d, ppm): 7.43–8.29 (m, 14H, Qui-H, Ar-H), 7.59
(s, 1H, –CH‚C–), 8.70 (s, 1H, –NHCO– linkage); 13C
NMR (400 MHz, DMSO-d6, d, ppm): 111.6, 126.8, 123.8,
127.3, 127.7, 127.9, 128.2, 128.5, 128.8, 129.4, 129.6, 132.2,
133.3, 136.4, 137.2, 138.7, 144.7, 145.3, 152.5, 153.1, 168.6,
172.4; LCMS (m/z): 497 (M+). Anal. Calcd. for C26H16ClN5-
O4: C – 62.72%, H – 3.24%, N – 14.07%; Found: C –
62.78%, H – 3.19%, N – 14.13%.
2.2.3.11. Physical constants and characterization of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazol-1-yl)-2-hydroxybenzamide (3i). IR (KBr, cm1):
3411 (O–H stretching, –OH group), 3347 (N–H stretching, sec-
ondary amine), 3054, 3081 (C–H stretching, aromatic ring),
3014 (C–H stretching, –CH‚C–), 1716 (C‚O stretching,
amide), 1677 (C‚O stretching, imidazoline ring), 1619, 1581,
1523 (C‚N, C‚C, aromatic ring stretching), 949 (C–H bend-
ing, –CH‚C–), 756 (C–Cl stretching); 1H NMR (400 MHz,
DMSO-d6, d, ppm): 7.38–8.23 (m, 14H, Qui-H, Ar-H), 7.52
(s, 1H, –CH‚C–), 8.63 (s, 1H, –NHCO– linkage), 9.46 (s,
1H, –OH); 13C NMR (400 MHz, DMSO-d6, d, ppm): 111.2,
117.2, 120.9, 121.2, 126.3, 127.1, 127.4, 127.9, 128.2, 128.5,
128.7, 129.1, 129.2, 132.2, 133.4, 133.8, 136.1, 137.2, 144.8,
145.6, 152.2, 156.6, 168.4, 172.1; LCMS (m/z): 468 (M+).
Anal. Calcd. for C26H17ClN4O3: C – 66.60%, H – 3.65%, N
– 11.95%; Found: C – 66.66%, H – 3.59%, N –11.90%.2.2.3.12. Physical constants and characterization of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazol-1-yl)-3-hydroxybenzamide (3j). IR (KBr, cm1):
3409 (O–H stretching, –OH group), 3353 (N–H stretching, sec-
ondary amine), 3060, 3085 (C–H stretching, aromatic ring),
3010 (C–H stretching, –CH‚C–), 1712 (C‚O stretching,
amide), 1682 (C‚O stretching, imidazoline ring), 1620, 1583,
1518 (C‚N, C‚C, aromatic ring stretching), 973 (C–H bend-
ing, –CH‚C–), 754 (C–Cl stretching); 1H NMR (400 MHz,
DMSO-d6, d, ppm): 7.41–8.25 (m, 14H, Qui-H, Ar-H), 7.50
(s, 1H, –CH‚C–), 8.65 (s, 1H, –NHCO– linkage), 9.41 (s,
1H, –OH); 13C NMR (400 MHz, DMSO-d6, d, ppm): 111.3,
115.6, 119.8, 120.7, 126.7, 127.4, 127.6, 127.4, 128.1, 128.4,
128.7, 129.2, 129.8, 132.6, 133.3, 135.3, 136.2, 137.5, 144.7,
145.5, 152.4, 156.7, 168.3, 172.1; LCMS (m/z): 468 (M+).
Anal. Calcd. for C26H17ClN4O3: C – 66.60%, H – 3.65%, N
– 11.95%; Found: C – 66.54%, H – 3.69%, N – 11.88%.
2.2.3.13. Physical constants and characterization of 4-chloro-N-
(4-((2-chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-
dihydro-1H-imidazol-1-yl)-2-hydroxybenzamide (3k). 7IR
(KBr, cm1): 3417 (O–H stretching, –OH group), 3363 (N–H
stretching, secondary amine), 3047, 3089 (C–H stretching, aro-
matic ring), 3021 (C–H stretching, –CH‚C–), 1719 (C‚O
stretching, amide), 1679 (C‚O stretching, imidazoline ring),
1614, 1590, 1512 (C‚N, C‚C, aromatic ring stretching), 964
(C–H bending, –CH‚C–), 749, 774 (C–Cl stretching); 1H
NMR (400 MHz, DMSO-d6, d, ppm): 7.48–8.31 (m, 13H, Qui-
H, Ar-H), 7.58 (s, 1H, –CH‚C–), 8.69 (s, 1H, –NHCO– link-
age), 9.57 (s, 1H, –OH); 13C NMR (400 MHz, DMSO-d6, d,
ppm): 111.4, 115.7, 118.5, 121.1, 126.7, 127.3, 127.4, 127.7,
128.4, 128.5, 128.8, 129.2, 130.6, 132.1, 133.5, 136.3, 137.7,
141.3, 144.3, 145.6, 152.3, 158.6, 168.7, 172.2; LCMS (m/z):
502 (M+). Anal. Calcd. for C26H16Cl2N4O3: C – 62.04%, H –
968 N.C. Desai et al.3.20%, N – 11.13%; Found: C – 62.10%, H – 3.26%, N –
11.18%.
2.2.3.14. Physical constants and characterization of N-(4-((2-
chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-4,5-dihydro-
1H-imidazole-1-yl)isonicotinamide (3l). IR (KBr, cm1): 3356
(N–H stretching, secondary amine), 3043, 3074 (C–H stretching,
aromatic ring), 3012 (C–H stretching, –CH‚C–), 1716 (C‚O
stretching, amide), 1678 (C‚O stretching, imidazoline ring),
1612, 1580, 1526 (C‚N, C‚C, aromatic ring stretching), 984
(C–H bending, –CH‚C–), 762 (C–Cl stretching); 1H NMR
(400 MHz, DMSO-d6, d, ppm): 7.44–8.67 (m, 14H, Qui-H, Ar-
H), 7.63 (s, 1H, –CH‚C–), 8.61 (s, 1H, –NHCO– linkage);
13C NMR (400 MHz, DMSO-d6, d, ppm): 111.6, 121.9, 126.3,
127.2, 127.7, 127.8, 128.3, 128.6, 128.8, 129.3, 132.3, 133.4,
136.2, 137.3, 139.8, 144.5, 145.3, 149.8, 152.1, 168.3, 172.4;
LCMS (m/z): 453 (M+). Anal. Calcd. for C25H16ClN5O2: C –
66.16%, H – 3.55%, N – 15.43%; Found: C – 66.22%, H –
3.61%, N – 15.37%.
3. Results and discussion
3.1. Chemistry
The synthetic pathway for compounds under consideration is
illustrated on the Scheme 1. The present scaffold 3a is a part
of synthesis of new chemical entities in form of antimicrobial
agents. Compound 4-((2-chloroquinolin-3-yl)methylene)-2-
phenyloxazol-5(4H)-one (2) is prepared in an excellent yield
in one step by Perkin condensation of hippuric acid, 2-chloro-
quinoline-3-carbaldehyde (1) and acetic anhydride in the pres-
ence of anhydrous sodium acetate. The condensation reaction
is carried out in microwave irradiation at 300 W intermittently
at 30 s intervals for 3 min. In the ﬁnal step, intermediate (2) is
reacted with N-aminoarylcarboxamides in pyridine and
reﬂuxed for a speciﬁed time (Table 1) to furnish the ﬁnal prod-
uct N-(4-((2-chloroquinolin-3-yl)methylene)-5-oxo-2-phenyl-
4,5-dihydro-1H-imidazol-1-yl)(aryl)amides (3a–l), while the
same product is obtained in microwave irradiation at 400 W
intermittently at 30 s intervals for a speciﬁed time (Table 1).
Classical method for the synthesis of (2) and (3a–l) required
4 and 6–9 h, respectively, for the completion of reaction. But
in the paper, we have received very good results from MWI
method for the synthesis of (2) and (3a–l). The same com-
pounds are synthesized in 3–6 min. These results clearly reveal
the superiority of MWI method over the classical procedure.
3.2. Characterization
Characterization of newly synthesized compounds of this ser-
ies was accomplished by IR, NMR and mass spectral data.
IR spectrum of title compound (3d) (molecular formula
C26H16Cl2N4O2, m.w. 487.34) has stretching vibration band
at 3348 cm1 over the range, showing medium intensity
absorption bands corresponding to secondary amine. Absorp-
tion bands 3045 and 3081 cm1 over the range are due to Ar-H
stretching vibrations. Medium intensity absorption peak at
3025 cm1 is due to stretching vibration of –CH‚C– linkage.
Strong intensity absorption band at 1684 cm1 is due to
stretching vibration of C‚O in imidazoline ring, while strong
intensity absorption band at 1715 cm1 is due to stretchingvibration of C‚O in amide linkage. Weak intensity absorp-
tion at 1605 cm1 corresponds to a C‚N stretching vibration
and medium intensity absorption stretching vibration of C‚C
appeared at 1588 and 1520 cm1 over the range. Bending
vibration in the range of 980 cm1 is due to –CH‚C– linkage.
Strong intensity absorption bands in the range of 748 and
768 cm1 are due to the stretching vibration of C–Cl bond.
In 1H NMR spectra, it has been observed from the chemical
structure of compound (3d) that different pairs of carbons e.g.
C-15 and C-19, C-16 and C-18, C-22 and C-26, C-23 and C-25
are attached to chemically equivalent protons. Protons
attached to C-15 and C-19 appeared at d= 7.86 ppm, while
protons attached to C-16 and C-18 appeared at
d= 7.40 ppm. Protons which are attached to C-22 and C-26
appeared at d= 7.92 ppm, while protons attached to C-23
and C-25 appeared at d= 7.45 ppm. Proton attached to C-2
position appeared as a multiplet at d= 7.49 ppm due to
mutual coupling with protons attached to C-1 and C-3,
appeared at d= 8.01 and 7.69 ppm, respectively. While proton
attached to C-3 position appeared as a multiplet at
d= 7.69 ppm due to mutual coupling with protons attached
to C-2 and C-4, which appeared at d= 7.49 and 7.92 ppm,
respectively. Proton attached to C-9 and present in quinoline
nucleus appeared as a singlet at d= 8.24 ppm, while proton
attached to C-10 appeared at d= 7.53 ppm. Proton attached
to C-17 appeared as a multiplet at a d= 7.40 ppm. Proton
attached at amide linkage appeared as a singlet at
d= 8.62 ppm, due to the inﬂuence of carbonyl group.
Looking to 13C NMR, chemical shift of the ﬁnal compound
(3d) varies from d= 111.3 to 172.1 ppm. Carbon nucleus under
the inﬂuence of a strong electronegative environment appeared
downﬁeld, e.g. C-20 i.e. carbonyl carbon, which is present in
amide linkage directly linked to nitrogen, has a chemical shift
value of d= 168.5 ppm. Carbonyl carbon C-13 of imidazoline
ring directly linked to nitrogen, has a chemical shift value of
d= 172.1 ppm. Carbon present in imidazoline nucleus C-12 is
directly attached to nitrogen atom on both sides, appeared at a
chemical shift value d= 144.8 ppm, while carbon of imidazo-
line C-11 showed a chemical shift at d= 137.3 ppm. Carbons
are present in quinoline nucleus at C-5 and C-7 both sides are
directly attached to nitrogen and C-7 is on other side directly
attached to chlorine atom. Due to this reason, C-5 carbon
showed chemical shift at d= 145.6 ppm and C-7 showed a
chemical shift at d= 152.4 ppm. Carbon of chlorophenyl ring
C-24 appeared at d= 138.2 ppm due to the inﬂuence of chloro
group. Carbon which is present in alkene linkage C-10 gave a
chemical shift at d= 111.3 ppm. Carbons of the quinoline ring
C-1, C-2, C-3, C-4, C-6, C-8 and C-9 showed a chemical shift
between d= 126.7 and 136.1 ppm. Carbons of the phenyl ring
C-14 to C-19 showed a chemical shift between d= 128.1 and
133.4 ppm. Carbons of the chloro phenyl ring C-21, C-22, C-
23, C-25 and C-26 showed a chemical shift between d= 128.7
and 131.1 ppm. Carbon enumeration of compound (3d) is
described in Fig. 1.3.3. Antimicrobial screening
Many of the newly synthesized compounds are found to exhi-
bit good to excellent antimicrobial activity. From antimicro-
bial activity data (Table 2), it is observed that compounds 3c
(3-Cl–C6H4), 3d (4-Cl–C6H4), 3f (4-F–C6H4), 3h (4-NO2–
Green synthesis of novel quinoline based imidazole derivatives 969C6H4) and 3j (3-OH–C6H4) are most active compounds. For
antibacterial activity, it has been observed that compounds
3a (–C6H5), 3e (2,5-(Cl)2–C6H3), 3g (3-NO2–C6H4), 3i (2-
OH–C6H4) and 3j (3-OH–C6H4) possess good activity, while
incorporation of chloro group at 3rd position of phenyl ring
in compound 3a to 3c increases the activity and it possesses
very good activity against Escherichia coli. It has been
observed from the data that when we replace chloro group
at 4th position of phenyl ring in 3a we get compound 3d,
and when we replace nitro group at 4th position of phenyl ring
in 3a we get compound 3h and it enhances the activity and pos-
sesses excellent activity against E. coli. Compounds 3c (3-Cl–
C6H4), 3d (4-Cl–C6H4), 3f (4-F–C6H4), 3g (3-NO2–C6H4), 3i
(2-OH–C6H4) and 3k (2-OH,4-Cl–C6H3) possess good activity
against Pseudomonas aeruginosa. When we substitute hydro-
gen in 3a by nitro group and hydroxyl group, it leads to corre-
sponding compounds 3h (4-NO2–C6H4) and 3j (3-OH–C6H4)
which possesses very good activity against P. aeruginosa. Com-
pounds 3b (C6H5–CH2), 3c (3-Cl–C6H4), 3d (4-Cl–C6H4), 3h
(4-NO2–C6H4), 3k (2-OH,4-Cl–C6H3) and 3l (–C5H4N) pos-
sess good activity against Staphylococcus aureus, while com-
pounds 3f (4-F–C6H4) and 3i (2-OH–C6H4) possess very
good activity against S. aureus. Compounds 3h (4-NO2–
C6H4) and 3l (–C5H4N) possess good activity against Strepto-
coccus pyogenes and compound 3d (4-Cl-C6H4) possesses very
good activity against S. pyogenes.
For antifungal activity, compounds 3a (–C6H5), 3i (2-OH–
C6H4) and 3k (2-OH,4-Cl–C6H3) possess good activity against
Candida albicans. When we replace hydrogen by chloro, nitro
and pyridine substituent in 3a it will give 3d, 3g, 3l respectively
and it possesses very good activity against C. albicans. Further-
more, replacement of hydrogen in 3a by 3-Cl–C6H4, 2,5-(Cl)2-
C6H3, 4-F-C6H4 and 4-NO2-C6H4 and enhances the activity
and it possesses excellent activity against C. albicans. Com-
pounds 3b (3-Cl–C6H4), 3d (4-Cl–C6H4), 3h (4-NO2–C6H4)
and 3j (3-OH-C6H4) possess good activity against A. niger.
Compounds 3c (3-Cl–C6H4), 3f (4-F–C6H4), 3g (3-NO2–
C6H4) and 3l (–C5H4N) possess good activity against Aspergil-
lus clavatus. Enhancement of activity of these compounds is
due to the presence of hydroxy, nitro and halogen groups in
title compounds. Thus, we have discussed and compared anti-
bacterial and antifungal activities based on standard drugs
ampicillin and griseofulvin, respectively.N Cl
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Figure 1 Carbon enumeration of ﬁnal compound (3d).3.4. Antibacterial assay
The newly synthesized compounds are screened for their anti-
bacterial activity against Gram-positive bacteria (S. aureus
(MTCC-96), S. pyogenes (MTCC-442)) and Gram-negative
(E. coli (MTCC-443), P. aeruginosa (MTCC-1688)). Antibacte-
rial activity is carried out by serial broth dilution method
(Desai et al., 2010, 2011a; Al-Bayati and Al-Mola, 2008). Stan-
dard strains which are used for antimicrobial activity are pro-
cured by The Institute of Microbial Technology, Chandigarh.
Compounds 3a–l were screened for their antibacterial activity
in six sets against E. coli, S. aureus, Pseudomonas aeruginosa
and S. pyogenes at different concentrations of 1000, 500,
200, 100, 50, 25 lg/mL as shown in Table 2. The drugs found
to be active in primary screening are similarly diluted to obtain
100, 50, 25 lg/mL concentrations. Ten microgram per millilitre
of suspensions is further inoculated on appropriate media andgrowth is noted after 24 and 48 h. The lowest concentration,
which shows no growth after spot subculture is considered as
MIC for each drug. The highest dilution showing at least
99% inhibition is taken as MIC. The test mixture should con-
tain 108 cells/mL. Standard drug used in the present study is
‘ampicillin’ for evaluating antibacterial activity which shows
100, 100, 250 and 100 lg/mL MIC against E. coli, P. aerugin-
osa, S. aureus and S. pyogenes, respectively. For bacterial
growth, in the present protocol, we have used Muller Hinton
broth at 37 C in aerobic condition for 24–48 h.
3.5. Antifungal assay
The same compounds are tested for antifungal activity in six sets
against C. albicans, Aspergillus niger and A. clavatus at various
concentrations of 1000, 500, 200 and 100 lg/mL as shown in
Table 2. Results are recorded in the formof primary and second-
ary screening. Synthesized compounds are diluted to 1000 lg/
mL concentration, as a stock solution. Synthesized compounds
which are found to be active in this primary screening are further
tested in second set of dilution against all microorganisms. The
lowest concentration, which shows no growth after spot subcul-
ture is considered as MIC for each drug. The highest dilution
showing at least 99% inhibition is taken as MIC. Test mixture
should contain 108 spores/mL MIC. Griseofulvin is used as a
standard drug for antifungal activity, which shows 500, 100
and 100 lg/mL MIC against C. albicans, A. niger and A. clava-
tus, respectively. Results of antimicrobial evaluation of deriva-
tives 3a–l are shown in Table 2. For fungal growth, in the
present protocol, we have used Sabourauds dextrose broth at
22 C in aerobic condition for 72 h.
3.6. Statistical analysis
Standard deviation value is expressed in terms of ±SD. On the
basis of calculated value by using one-way ANOVA method
followed by independent two sample t test, it has been
observed that differences below 0.001 level are considered as
statistically signiﬁcant. Compounds (3a–l) are screened for
their antibacterial and antifungal activities in six sets (n)
against bacteria and fungi used in the present protocol.
3.7. SAR studies
The substitution pattern of the quinoline-imidazole derivatives
was carefully selected to confer different electronic environ-
Table 2 Results of antibacterial and antifungal screening of compounds 3a–l.
Sr. No. –R Minimum inhibitory concentration (MIC) (lg/mL) ± SD Minimum inhibitory concentration (MIC) (lg/mL) ± SD
E. coli P. aeruginosa Staphylococcus aureus Streptococcus pyogenes C. albicans A. niger A. clavatus
MTCC 443 MTCC 1688 MTCC 96 MTCC 442 MTCC 227 MTCC 282 MTCC 1323
3a –C6H5 100 ± 2.03
** 500 ± 2.64* 1000 ± 3.78 500 ± 2.64 500 ± 2.64* 500 ± 3.05* 1000 ± 3.21
3b C6H5–CH2– 500 ± 3.46
* 500 ± 3.46 250 ± 3.21** 250 ± 3.04*** 1000 ± 1.04** 1000 ± 2.51** 500 ± 4.05*
3c –3-Cl–C6H4 50 ± 2.64
*** 100 ± 1.21** 200 ± 2.08* 1000 ± 4.51 100 ± 1.51* 1000 ± 4.50 100 ± 1.64*
3d –4-Cl–C6H4 25 ± 1
* 100 ± 1.51* 200 ± 2.08** 50 ± 2.64** 200 ± 2.64* 100 ± 1.21** 500 ± 4.16
3e –2,5-(Cl)2–C6H3 100 ± l 250 ± 2.51
** 1000 ± 4.04 1000 ± 2.51* 100 ± 2.51** 500 ± 2.08*** 500 ± 3.78**
3f –4-F–C6H4 200 ± 1.62
* 100 ± 1.60 100 ± 2.78** 1000 ± 3.78** 100 ± 1.78* 1000 ± 3.05 100 ± 2.78***
3g –3-NO2–C6H4 100 ± l
** 100 ± 1.72 500 ± 3.05 250 ± 2.51*** 200 ± 3.51 500 ± 4.05* 100 ± 1.51*
3h –4-NO2–C6H4 25 ± 1.62
*** 50 ± 1.05* 250 ± 2.16* 100 ± 1.78** 100 ± 3.78** 100 ± l*** 200 ± 3.05**
3i –2-OH–C6H4 100 ± 2.15
* 100 ± l*** 100 ± 2.04* 500 ± 4.50 500 ± 4.50* 250 ± 3.78** 500 ± 4.58
3j –3-OH–C6H4 100 ± 2.05
* 50 ± 1.16** 500 ± 4.50 200 ± 2.05* 1000 ± 2.05*** 100 ± 2.05*** 500 ± 3.21**
3k –2-OH,4-Cl–C6H3 200 ± 2.21
* 100 ± 2.15** 250 ± 2.64** 500 ± 3.08 500 ± 2.08 250 ± 2.05 500 ± 3.46
3l –C5H4N 500 ± 3.05
** 500 ± 3.78 250 ± 3.21* 100 ± 1.51* 200 ± 3.51** 500 ± 2.64* 100 ± 1.12*
Ampicillin 100 ± 2.05 100 ± 1.0 250 ± 1.52 100 ± 2.06 – – –
Griseofulvin – – – – 500 ± 2.58 100 ± l 100 ± 1.15
±SD= Standard deviation. All values are presented as mean of six experiments (n= 6). All signiﬁcant differences are considered from control
value 0.00.
* Signiﬁcant P< 0.05.
** Moderately signiﬁcant P< 0.01.
*** Extremely signiﬁcant P < 0.001.
970 N.C. Desai et al.ment to the molecules. Thus, electron donating groups to aro-
matic ring, such as phenyl, hydroxyl and pyridine and electron
withdrawing groups from aromatic ring, such as nitro and hal-
ogen were chosen as substituents on the chemical structure of
the target compounds. Compounds 3d and 3h, bearing electron
withdrawing groups, exhibit stronger antibacterial activity
(MIC 25 lg/mL) than reference drug ampicillin against
Gram-negative bacteria E. coli. However, nitro, hydroxy and
phenyl substituted compounds are found to be as effective as
reference drug against E. coli. On the other hand, compounds
prepared to contain electron donating groups, showed higher
MIC value than ampicillin against most bacterial strains.
Compounds 3h containing nitro group and 3j containing
hydroxy group were the most active derivatives against P.
aeruginosa. Compound 3f (MIC 100 lg/mL) containing ﬂuoro
group and 3d (MIC 50 lg/mL) containing chloro group
showed more potency against Gram-positive bacteria S. aureus
and S. pyogenes, respectively. Compounds 3c, 3e, 3f and 3h
containing electron withdrawing groups chloro, ﬂuoro and
nitro showed stronger activity than standard drug griseofulvin
against almost all fungal strains. Among all the compounds
selected, electron withdrawing substituents such as chloro, ﬂu-
oro and nitro compounds possessed wider antibacterial spec-
trum than the others. Thus, our aim was to explore SAR
trends and to ﬁnd out the lead for further optimization.4. Conclusion
Demands for new bio-active molecules in the ﬁeld of health
care, combined with the pressure to produce these substances
expeditiously and in an environmentally benign fashion, pose
signiﬁcant challenges to the synthetic chemical community.
We have successfully synthesized heterocyclic compounds by
using green techniques, such as selective MW heating of neat
reactants under solvent-free conditions. In general, improve-
ments in rate and yield of reactions are observed in MWI.When organic reactions are carried out under microwave as
compared to classical conditions, it may be observed that acti-
vation occurs at different temperatures with these techniques
and, therefore strict comparisons will require a balance
between effectiveness and energy costs. We have found com-
pounds 3c, 3d, 3f, 3h and 3j the most distinctive derivatives
identiﬁed in present study because of their remarkable
in vitro antimicrobial potency. Therefore, such compounds
would represent a fruitful matrix for the development of anti-
microbial candidates. Efforts are currently being taken up to
optimize the lead structure and results of which will be the
basis of our future research endeavour.
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